Based upon changes in apixaban exposure explained in the product label for additional concomitant medications, body size, and organ function, no further dose adjustment is definitely suggested for patients comedicated with cyclosporine or tacrolimus. Funding The funds to conduct this investigator\initiated study were provided by an ARISTA\USA grant administered by Bristol\Myers Squibb and Pfizer. a […]